PCVX
Vaxcyte Inc

743
Mkt Cap
$5.96B
Volume
2.21M
52W High
$94.76
52W Low
$27.66
PE Ratio
-9.89
PCVX Fundamentals
Price
$48.69
Prev Close
$45.55
Open
$45.62
50D MA
$39.48
Beta
0.71
Avg. Volume
1.71M
EPS (Annual)
-$3.80
P/B
2.19
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Los Angeles Capital Management LLC Acquires Shares of 39,462 Vaxcyte, Inc. $PCVX
Los Angeles Capital Management LLC bought a new stake in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange...
MarketBeat·20h ago
News Placeholder
More News
News Placeholder
Nan Fung Trinity HK Ltd. Takes $3.39 Million Position in Vaxcyte, Inc. $PCVX
Nan Fung Trinity HK Ltd. acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the second quarter, according to its most recent disclosure with the Securities and Exchange...
MarketBeat·2d ago
News Placeholder
Profund Advisors LLC Has $1.14 Million Holdings in Vaxcyte, Inc. $PCVX
Profund Advisors LLC grew its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 23.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and...
MarketBeat·2d ago
News Placeholder
Vaxcyte's (PCVX) "Buy" Rating Reiterated at BTIG Research
BTIG Research reiterated a "buy" rating and set a $85.00 target price on shares of Vaxcyte in a research note on Monday...
MarketBeat·4d ago
News Placeholder
Campbell & CO Investment Adviser LLC Invests $2.41 Million in Vaxcyte, Inc. $PCVX
Campbell & CO Investment Adviser LLC bought a new stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 2nd quarter, according to its most recent filing with the SEC. The institutional...
MarketBeat·5d ago
News Placeholder
Cantor Fitzgerald Reduces Earnings Estimates for Vaxcyte
Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Cantor Fitzgerald lowered their FY2025 earnings estimates for Vaxcyte in a report released on Thursday, November 6th. Cantor...
MarketBeat·5d ago
News Placeholder
Vaxcyte, Inc. $PCVX Shares Purchased by C WorldWide Group Holding A S
C WorldWide Group Holding A S boosted its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 105.3% in the second quarter, according to its most recent filing with the Securities and...
MarketBeat·8d ago
News Placeholder
2 ‘Strong Buy’ Growth Stocks That Could Gain More Than 340%
A volatile market presents the perfect opportunity to grab outstanding stocks at a bargain.
barchart.com·7mo ago
News Placeholder
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm
Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Vaxcyte, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK, Jan. 7, 2025...
PR Newswire·10mo ago
News Placeholder
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's...
Benzinga·1y ago

Latest PCVX News

View

Advertisement|Remove ads.

Advertisement|Remove ads.